Author:
Saad F,Ivanescu C,Phung D,Loriot Y,Abhyankar S,Beer T M,Tombal B,Holmstrom S
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Urology,Oncology
Reference33 articles.
1. Butoescu V, Tombal B . Practical guide to bone health in the spectrum of advanced prostate cancer. Can J Urol 2014; 21 (Suppl 1): 84–92.
2. Hotte SJ, Saad F . Current management of castrate-resistant prostate cancer. Curr Oncol 2010; 17 (Suppl 2): S72–S79.
3. Brown JE, Sim S . Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia 2010; 12: 685–696.
4. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et alZoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879–882.
5. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et alPREVAIL Investigators.. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424–433.
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献